Thierry Facon

8PUBLICATIONS
42CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Haematological tumoursMedical mycologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 06, 2026
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

|Sep 25, 2026
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Mar 27, 2025
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential.

Walter M Gregory, Thomas J Prior, J Blake Bartlett

|Jan 02, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.

Thierry Facon, Gordon Cook, Saad Z Usmani

|Feb 19, 2017
Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Salomon Manier, Chia-Jen Liu, Hervé Avet-Loiseau

Pageof 2

Frequent Collaborators

6 joint publications

Saad Z Usmani

5 joint publications

Sonja Zweegman

5 joint publications

Supratik Basu

4 joint publications

Cyrille Hulin